多柔比星、博来霉素、长春碱和达卡巴嗪联合有限野放疗治疗I-IIA期霍奇金淋巴瘤后长期发病率仍有限度升高但未消除
该研究纳入1999-2005年瑞典215例接受2或4周期ABVD联合30 Gy有限野放疗的I-IIA期经典型霍奇金淋巴瘤患者,与860名匹配对照比较,中位随访16年,发现恶性肿瘤、循环系统疾病和呼吸系统疾病风险仍升高,但超额发病率低于既往报道。
要点
- 有限野放疗后恶性肿瘤风险仍升高(HR 1.5,95%CI 1.0-2.4)。
- 循环系统疾病风险升高(HR 1.5),其中仅静脉血栓栓塞显著升高。
- 呼吸系统疾病风险升高(HR 2.6),主要由哮喘驱动(HR 3.5)。
核心结论
- 与早期放疗技术相比,超额发病率未消除,但低于既往报道。
- 呼吸系统疾病风险升高由哮喘诊断驱动,部分可能为持续性肺毒性误诊。
研究设计与样本
- 研究纳入1999-2005年瑞典所有接受2或4周期ABVD联合30 Gy有限野放疗的经典型霍奇金淋巴瘤患者(n=215),并与按年龄、性别和居住地区匹配的对照(n=860)比较。
- 通过国家健康登记处交叉核对恶性肿瘤、循环系统疾病和呼吸系统疾病,从霍奇金淋巴瘤诊断日开始随访。
主要发现
- 患者恶性肿瘤风险高于对照,HR 1.5(95%CI 1.0-2.4)。
- 患者循环系统疾病风险高于对照,HR 1.5(95%CI 1.1-2.0);其中仅静脉血栓栓塞显著升高。
- 排除前6个月并在霍奇金淋巴瘤复发或任何恶性肿瘤诊断时删失后,静脉血栓栓塞的HR升高减弱。
- 患者呼吸系统疾病风险高于对照,HR 2.6(95%CI 1.6-4.3);超额风险大部分由哮喘构成,HR 3.5(95%CI 1.8-6.8)。
- 诊断呼吸系统疾病的患者显著年轻于对照。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Balancing disease control and toxicity from chemotherapy and radiotherapy (RT) when treating early-stage classical Hodgkin lymphoma (cHL) is important. Available data on long-term toxicity after RT for cHL mostly refer to RT techniques no longer in use. We aimed to describe long-term toxicity from modern limited-field (LF)-RT after two or four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). PATIENTS AND METHODS: This study included all patients with cHL treated with two or four cycles of ABVD and 30 Gy LF-RT during 1999-2005 in Sweden. Patients (n = 215) and comparators (n = 860), matched for age, gender, and region of residence, were cross-checked against national health registries for malignancies, diseases of the circulatory system (DCS), and diseases of the respiratory system (DRS) from the day of diagnosis of cHL. RESULTS: The risk of a malignancy was higher for patients than comparators, hazard ratio (HR) 1.5 (95% CI, 1.0 to 2.4), as was the risk for DCS 1.5 (95% CI, 1.1 to 2.0) and for DRS 2.6 (95% CI, 1.6 to 4.3). The median follow-up was 16 years (range, 12-19 years). Of individual diagnoses in DCS, only venous thromboembolism was statistically significantly elevated. If the first 6 months (ie, time of active treatment for cHL) were excluded and censoring at relapse of cHL or diagnosis of any malignancy, the increased HR for venous thromboembolism diminished. Most of the excess risk for DRS consisted of asthma, HR 3.5 (95% CI, 1.8 to 6.8). Patients diagnosed with DRS were significantly younger than comparators. CONCLUSION: Compared with toxicity from earlier RT techniques, excess morbidity was not eliminated, but lower than previously reported. The elevated risk of DRS was driven by diagnosis of asthma, which could in part be explained by misdiagnosis of persisting pulmonary toxicity.
引用
- Lagerlöf I, Fohlin H, Enblad G, et al. Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. J Clin Oncol. 2022. PMID: 35077204. doi:10.1200/JCO.21.02407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。